May 2005
Volume 46, Issue 13
ARVO Annual Meeting Abstract  |   May 2005
Safety of Intraocular Ketorolac
Author Affiliations & Notes
  • L.J. Kugler
    University Of Nebraska Medical Center, Omaha, NE
  • M.V. Brumm
    Johns Hopkins University School of Medicine, Baltimore, MD
  • G.R. Christensen
    University Of Nebraska Medical Center, Omaha, NE
  • J.L. Meza
    Department of Preventive and Societal Medicine,
    University Of Nebraska Medical Center, Omaha, NE
  • E. Margalit
    University Of Nebraska Medical Center, Omaha, NE
  • Footnotes
    Commercial Relationships  L.J. Kugler, None; M.V. Brumm, None; G.R. Christensen, None; J.L. Meza, None; E. Margalit, None.
  • Footnotes
    Support  Allergan pharmaceuticals
Investigative Ophthalmology & Visual Science May 2005, Vol.46, 1460. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      L.J. Kugler, M.V. Brumm, G.R. Christensen, J.L. Meza, E. Margalit; Safety of Intraocular Ketorolac . Invest. Ophthalmol. Vis. Sci. 2005;46(13):1460.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Abstract: : Purpose: Many retina specialists are injecting triamcinolone into the vitreous to treat diseases such as cystoid macular edema, diabetic macular edema, uveitis, and even age related macular degeneration. Common side effects of this treatment include cataract development and high intraocular pressure. Another alternative to treat such diseases could be intraocular nonsteroidal anti–inflammatory drugs (NSAIDs). Topical NSAIDs are known to be less cataractogenic, and not cause intraocular pressure elevation. Thus, we tried to determine whether ketorolac trometamol, an NSAID, is non–toxic to the retina when injected into the vitreous of rabbits. Methods: One tenth of a milliliter of preservative–free ketorolac trometamol was injected into the vitreous of the right eye of 15 Dutch–belted rabbits. Eight rabbits were injected with 0.5% ketorolac and seven rabbits were injected with 0.25% ketorolac. One tenth of a milliliter of balanced saline solution (BSS) was injected into the left eye of each rabbit as a control. A standard electroretinogram was obtained prior to injection, and repeated one day, one week, two weeks, three weeks, and four weeks after injection. After four weeks the rabbits were euthanized and the eyes enucleated for histopathologic examination by light and electron microscopy. Differences in the electroretinograms and histopathology between the two eyes were compared. Results: There were no statistically significant differences in electroretinograms obtained between the ketorolac eyes and the control eyes. No histopathological changes were observed in the study eyes compared to the control eyes. Conclusions: Ketorolac trometamol is non–toxic to the retina of rabbits when injected intravitreally, and could be examined as an alternative to intraocular steroid injections.

Keywords: drug toxicity/drug effects • inflammation • macula/fovea 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.